HEC585
Phase 3Small molecule
Sunshine Lake Pharma Co., Ltd.HEC585 is one of 31 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Interstitial Lung Disease
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Tracleer
Johnson & JohnsonApproved
Trexall
Jazz PharmaceuticalsApproved
Actemra
RocheApproved
Medrol
PfizerApproved
Esbriet
LLegacy Health System
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Imuran
LLegacy Health System
Approved
Ofev
Boehringer IngelheimPhase 3
Avinza
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
IPF2 trials
Female2 trials
Interstitial Lung Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HEC585. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details